A small-molecule antivirulence agent for treating Clostridium difficile infection-Reference-Cited by-同舟云学术

A small-molecule antivirulence agent for treating Clostridium difficile infection

Published:2015-09-23 Issue:306 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Bender Kristina Oresic¹,Garland Megan¹,Ferreyra Jessica A.²,Hryckowian Andrew J.²,Child Matthew A.¹,Puri Aaron W.¹,Solow-Cordero David E.³,Higginbottom Steven K.²,Segal Ehud¹,Banaei Niaz¹⁴,Shen Aimee⁵,Sonnenburg Justin L.²,Bogyo Matthew¹²

Affiliation:

1. Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305–5324, USA.

2. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305–5124, USA.

3. Stanford University High-Throughput Bioscience Center, 1291 Welch Road, Stanford, CA 94305–5174, USA.

4. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305–5107, USA.

5. Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.

Abstract

A high-throughput screen against the Clostridium difficile toxin B cysteine protease domain identified a drug in clinical trials that reduced C. difficile pathology in a mouse model.

Funder

NIH

Stanford Office of Technology Licensing

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference64 articles.

1. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

2. Center for Disease Control and Prevention Antibiotic Resistance Threats in the United States 2013 (CDC Atlanta GA 2013).

3. R. Douglas Scott II The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention Division of Healthcare Quality Promotion National Center for Preparedness Detection and Control of Infectious Diseases. Coordinating Center for Infectious Diseases (CDC Atlanta GA 2009).

4. Burden of Clostridium difficile on the Healthcare System

5. Therapy ofClostridium difficileinfection: perspectives on a changing paradigm

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to fight bacteria without inducing drug resistance?;Nanotechnology Tools for Infection Control;2025

2. Clostridioides difficileToxins Unhinged: Allosterically Switchable Network Orientsβ-flap;2024-08-08

3. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options;Clinical Microbiology Reviews;2024-06-13

4. Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning;Frontiers in Pharmacology;2024-06-07

5. New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation;Gut Microbes;2024-04-09